June 09, 2014
The Second Circuit on Monday found that Shire LLC didn't block generic competition for its attention-deficit-hyperactivity drug Adderall XR, saying a lower court was correct to dismiss a consolidated class action because Shire's patent licensing agreements didn't raise an antitrust issue.
March 17, 2014
Attorneys for drug wholesalers claiming Shire LLC smothered generic competition for attention-deficit-hyperactivity drug Adderall XR told a Second Circuit panel Monday that a district court wrongly concluded that Shire's alleged breaches of patent licensing agreements aren't actionable under federal antitrust law.
October 04, 2013
Shire LLC pushed back Friday against two drug wholesalers' bid to revive a consolidated class action alleging Shire stifled generic-drug competition for its blockbuster attention deficit hyperactivity disorder treatment Adderall XR, saying the lower court correctly ruled that Shire's patent licensing agreements didn't raise an antitrust issue.